---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034169"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:17:52.240213+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics gets Nasdaq extension to regain compliance by June 15, 2025

## Summary
- Panel granted extension; must meet bid price rule by April 25, 2025, all other rules by June 15, 2025.
- Company transferring to Nasdaq Capital Market; previously failed MVLS ($50M), MVPHS ($15M), and bid price ($1) rules.
- Hearing held Feb 13, 2025; Panel accepted Company's compliance plan.
- CEO Hing C. Wong expressed optimism about executing strategy and advancing immunotherapies.

## SEC filing metadata
- accession: 0000950170-25-034169
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/0000950170-25-034169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/hcwb-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034169
- JSON: https://secwatch.observer/filing/0000950170-25-034169.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034169.txt

## Key facts
- Listing & Compliance Notices
  HCW Biologics Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: hearing update
  - Deficiency: minimum bid price
  - Rules: 5810(c)(3)(A)
  source text: ously disclosed, on February 5, 2025, the Company received written notice from the Staff that its securities were subject to delisting from Nasdaq since the Company did not regain compliance with the requirement to maintain a minimum bid price of $1 per share, in accordance with Nasdaq Listing Rule 5810(c)(3)(A) (“Bid Price Rule”) and the requirement to maintain the minimum $15,000,000 market value of publicly held securities (“MVPHS”) threshold required for continued listing on The Nasdaq Global Market ® under Nasdaq Listing Rule 5450(b)(2)C) (the “MVPHS Rule”). On March 3, 2025, the Panel gr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/0000950170-25-034169-index.htm
- Listing & Compliance Notices
  HCW Biologics Inc. received a nasdaq hearing update notice regarding market value (rules 5450(b)(3)(A), 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: hearing update
  - Deficiency: market value
  - Rules: 5450(b)(3)(A), 5450(b)(2)(C)
  source text: arket LLC (“Nasdaq” or the “Exchange”) that its securities were subject to delisting from Nasdaq since the Company did not regain compliance with the $50,000,000 market value of listed securities (“MVLS”) threshold required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the “MVLS Rule”). The Company made a timely request for a hearing before the Nasdaq Hearings Panel (the “Panel”) and was granted a hearing date on February 13, 2025. As previously disclosed, on February 5, 2025, the Company received written notice from the Staff that its securities we
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/0000950170-25-034169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.